A Randomized Controlled, Open-lable, Phase III, Multicenter Clinical Study of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation
Latest Information Update: 25 Sep 2021
At a glance
- Drugs Aumolertinib (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Jiangsu Hansoh Pharmaceutical
- 09 Jul 2021 New trial record